These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 33332042)

  • 1. [Cutaneous lesions in COVID-19 patients].
    Çiftçi Z; Clabbers JMK; Galimont-Collen AFS; Gostyński A
    Ned Tijdschr Geneeskd; 2020 Dec; 164():. PubMed ID: 33332042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous signs in COVID-19 patients: A review.
    Wollina U; Karadağ AS; Rowland-Payne C; Chiriac A; Lotti T
    Dermatol Ther; 2020 Sep; 33(5):e13549. PubMed ID: 32390279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of COVID-19 Chilblains-like Lesions and their Differential Diagnosis.
    Adv Skin Wound Care; 2021 Jul; 34(7):1. PubMed ID: 34125733
    [No Abstract]   [Full Text] [Related]  

  • 4. Coronavirus (COVID-19) Infection-Induced Chilblains: A Brisk Perieccrine Inflammatory Response.
    Wargo JJ; Weir NM; Shamma HN
    Am J Dermatopathol; 2021 Feb; 43(2):144-145. PubMed ID: 32618705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases.
    Colmenero I; Santonja C; Alonso-Riaño M; Noguera-Morel L; Hernández-Martín A; Andina D; Wiesner T; Rodríguez-Peralto JL; Requena L; Torrelo A
    Br J Dermatol; 2020 Oct; 183(4):729-737. PubMed ID: 32562567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathologic Features of Chilblainlike Lesions Developing in the Setting of the Coronavirus Disease 2019 (COVID-19) Pandemic.
    Sohier P; Matar S; Meritet JF; Laurent-Roussel S; Dupin N; Aractingi S
    Arch Pathol Lab Med; 2021 Feb; 145(2):137-144. PubMed ID: 33501498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous manifestations of COVID-19.
    Wang CJ; Worswick S
    Dermatol Online J; 2021 Jan; 27(1):. PubMed ID: 33560783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID toes: where do we stand with the current evidence?
    Baeck M; Herman A
    Int J Infect Dis; 2021 Jan; 102():53-55. PubMed ID: 33075530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 skin manifestations: the new great imitator?
    Shi V; Hsiao JL; Shi VY
    Dermatol Online J; 2020 Nov; 26(11):. PubMed ID: 33342186
    [No Abstract]   [Full Text] [Related]  

  • 10. Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries.
    Freeman EE; McMahon DE; Lipoff JB; Rosenbach M; Kovarik C; Takeshita J; French LE; Thiers BH; Hruza GJ; Fox LP;
    J Am Acad Dermatol; 2020 Aug; 83(2):486-492. PubMed ID: 32479979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological findings in COVID-19-induced cutaneous lesions. Clinicopathological correlation of SARS-CoV-19 dermatologic patterns: review of the literature.
    Nieto-Benito LM; Hernández de la Torre-Ruiz E; Balaguer-Franch I; Rosell-Díaz ÁM; Mateos-Mayo A; Herrero-Sanchez A; Lacasta-Plasín C; García-Piqueras P; Barchino-Ortiz L; Bergón-Sendín M; Pulido-Pérez A; Baniandrés-Rodríguez O; Rodriguez-Lomba E; Molina-Lopez I; Suárez-Fernandez R
    Australas J Dermatol; 2021 Feb; 62(1):e98-e101. PubMed ID: 32920868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous Manifestations of COVID-19.
    Schwartzberg L; Lin A; Jorizzo J
    Cutis; 2021 Feb; 107(2):90-94. PubMed ID: 33891838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinicopathological description of COVID-19-induced chilblains (COVID-toes) correlated with a published literature review.
    Kolivras A; Thompson C; Pastushenko I; Mathieu M; Bruderer P; de Vicq M; Feoli F; Harag S; Meiers I; Olemans C; Sass U; Dehavay F; Fakih A; Lam-Hoai XL; Marneffe A; Van De Borne L; Vandersleyen V; Richert B
    J Cutan Pathol; 2022 Jan; 49(1):17-28. PubMed ID: 34272741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous manifestations of COVID-19 and COVID-19 vaccination.
    Nakashima C; Kato M; Otsuka A
    J Dermatol; 2023 Mar; 50(3):280-289. PubMed ID: 36636825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraviral eruptions in the era of COVID-19: Do some skin manifestations point to a natural resistance to SARS-CoV-2?
    Lipsker D
    Clin Dermatol; 2020; 38(6):757-761. PubMed ID: 33341210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No SARS-CoV-2 antibody response in 25 patients with pseudo-chilblains.
    Docampo-Simón A; Sánchez-Pujol MJ; Gimeno-Gascon A; Palazón-Cabanes JC; Juan-Carpena G; Vergara-De Caso E; González-Villanueva I; Blanes-Martínez M; Betlloch-Mas I
    Dermatol Ther; 2020 Nov; 33(6):e14332. PubMed ID: 32975345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and clinical evolution of non-multisystem inflammatory syndrome (MIS-C) dermatological lesions in pediatric patients affected by SARS-CoV-2 infection: A systematic review of the literature.
    Dondi A; Sperti G; Gori D; Guaraldi F; Montalti M; Parini L; Piraccini BM; Lanari M; Neri I
    Eur J Pediatr; 2022 Oct; 181(10):3577-3593. PubMed ID: 35948654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chilblain-like lesions with prominent bullae in a patient with COVID-19.
    Rubin A; Alamgir M; Rubin J; Rao BK
    BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33139373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of SARS-CoV-2 antibodies in 24 patients presenting with chilblains-like lesions during the COVID-19 pandemic.
    Stavert R; Meydani-Korb A; de Leon D; Osgood R; Blau J; Luu T
    J Am Acad Dermatol; 2020 Dec; 83(6):1753-1755. PubMed ID: 32822790
    [No Abstract]   [Full Text] [Related]  

  • 20. Delayed hypersensitivity as a pathophysiological mechanism in cutaneous lesions due to SARS-CoV-2.
    Rafai M; Elbenaye J; Sabry S; Janah H
    Pan Afr Med J; 2020; 35(Suppl 2):115. PubMed ID: 33282070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.